Ataluren (PTC124™) for Genetic Disorders

PTC is currently developing ataluren, a novel, orally administered, small-molecule, investigational new drug for the treatment of genetic disorders in which a nonsense mutation is the cause of disease.

For more information on our clinical results, or ataluren, please visit the ataluren page of our website.

Ataluren Genetic Disorders

PTC299 Oncology